What is Novelix Pharmaceuticals share price return in the past 10 years?

Novelix Pharmaceuticals Ltd share price has appreciated 19.2% annually (CAGR) over the past ten years.

What is the P/E ratio of Novelix Pharmaceuticals?

The latest standalone P/E ratio of Novelix Pharmaceuticals as of 18-Jul-2025 is 730.59.

What is the P/B ratio of Novelix Pharmaceuticals?

The latest standalone P/B ratio of Novelix Pharmaceuticals as of 18-Jul-2025 is 2.58.

What is the 52-week high and low of Novelix Pharmaceuticals?

The 52-week high of Novelix Pharmaceuticals is Rs. 52.79 and the 52-week low is Rs. 19.88.

Novelix Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Novelix Pharmaceuticals
Brand: Novelix Pharmaceuticals

BSE: 536565 | NSE: | Trading | Small Cap

Place order

Novelix Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 536565 | NSE: | Trading | Small Cap

Place order

DeciZen - make an informed investing decision on Novelix Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Novelix Pharmaceuticals stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

730.59

Market Cap:

60.6 Cr.

52-wk low:

19.9

52-wk high:

52.8

Is Novelix Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Novelix Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Novelix Pharmaceuticals Ltd is a below average quality company.

2. Is Novelix Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Novelix Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Novelix Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Novelix Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Novelix Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0.8%	1.2%	1.8%	2.5%	1.6%	0.9%	-31.3%	-19.5%	-0.8%	0.3%	-
Value Creation Index ⓘ	-0.9	-0.9	-0.9	-0.8	-0.9	-0.9	-3.2	-2.4	-1.1	-1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1.5	0.9	3.5	3.1	3.6	1	1	0.8	1.4	4.2	31
Sales YoY Gr.	-	-36.3%	277.4%	-11.4%	15.4%	-71.3%	-1.9%	-16.8%	66.7%	201.4%	-
Adj EPS ⓘ	0.2	0.1	0.1	0.3	0.2	0.1	-4	-0.6	-0.3	-0.1	0.1
YoY Gr.	-	-55%	-22.2%	271.4%	-23.1%	-60%	-5137.5%	NA	NA	NA	-
BVPS (₹) ⓘ	14	14.1	14.3	14.6	14.8	14.9	10.9	8.9	8.9	9.1	18.2
Adj Net Profit ⓘ	0.2	0.1	0.1	0.2	0.2	0.1	-3.3	-0.5	-0.2	-0.1	0
Cash Flow from Ops. ⓘ	-0.4	2	-1.1	1.1	-0.4	1.2	0.6	0.6	-2.4	-0.3	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12.5%	3.3%	61.1%	201.4%
Adj EPS ⓘ	-189%	-181.1%	NA	NA
BVPSⓘ	-4.7%	-9.4%	-5.8%	2.3%
Share Price	19.2%	68.3%	80.3%	135.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	1.4	0.6	0.5	1.8	1.3	0.5	-31.3	-6.2	-3.2	-0.8	0.4
Op. Profit Mgn % ⓘ	47.7	42.7	5.2	15.3	5	-27.6	-346.8	-62	-36.9	-5.9	0.5
Net Profit Mgn % ⓘ	11.2	7.5	1.7	6.8	4.4	6.3	-324.1	-58.9	-16.4	-1.4	0.3
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	2,364	3,301	859	1,033	890	2,851	1,888	1,123	779	345	97
Cash Conv. Cycle ⓘ	145	25	32	85	153	407	87	207	209	94	69

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.40%

Sales growth is growing at healthy rate in last 3 years 61.06%

Sales growth is good in last 4 quarters at 899.98%

No data to display

Latest Financials - Novelix Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0.1	-1.2
TTM Sales (₹ Cr.)	30.7	1.2
BVPS (₹.) ⓘ	18.2	0
Reserves (₹ Cr.) ⓘ	11	2
P/BV ⓘ	2.58	0.00
PE ⓘ	730.59	0.00

From the Market
52 Week Low / High (₹)	19.88 / 52.79
All Time Low / High (₹)	1.85 / 74.60
Market Cap (₹ Cr.)	60.6
Equity (₹ Cr.)	12.9
Face Value (₹)	10
Industry PE ⓘ	45.2

Management X-Ray of Novelix Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Novelix Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Novelix Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1.46	0.93	3.51	3.11	3.59	1.03	1.01	0.84	1.40	4.22
Operating Expenses ⓘ	0.97	0.53	3.33	2.68	3.41	1.32	4.52	2.89	1.92	4.47
Manufacturing Costs	0.01	0.02	0.02	0	0.01	0.02	0.01	0.03	0.04	0.05
Material Costs	0.32	0	2.85	2.11	2.77	0.76	1.02	0.81	1.35	3.84
Employee Cost	0.04	0.09	0.07	0.13	0.18	0.13	0.15	0.14	0.16	0.13
Other Costs ⓘ	0.59	0.42	0.40	0.43	0.46	0.41	3.33	1.91	0.37	0.46
Operating Profit ⓘ	0.49	0.40	0.18	0.43	0.18	-0.29	-3.51	-2.05	-0.52	-0.25
Operating Profit Margin (%)	33.4%	42.6%	5.2%	13.9%	5.0%	-27.9%	-348.0%	-242.0%	-36.9%	-5.9%
Other Income ⓘ	0	0.08	0.14	0.01	0.13	0.47	0.32	0.55	0.52	0.31
Interest ⓘ	0	0	0	0	0	0	0	0	0	0
Depreciation ⓘ	0.40	0.34	0.12	0.15	0.12	0.08	0.08	0.07	0.06	0.04
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0.09	0.14	0.20	0.29	0.19	0.11	-3.27	-1.57	-0.06	0.02
Tax ⓘ	0.07	0.04	0.05	0.11	-0.06	0.01	0	-0.01	0	0.01
Profit After Tax	0.02	0.10	0.15	0.18	0.25	0.09	-3.27	-1.56	-0.06	0.01
PAT Margin (%)	1.3%	10.6%	4.3%	5.8%	7.0%	9.2%	-324.0%	-185.0%	-4.3%	0.2%
Adjusted EPS (₹)	0.0	0.1	0.2	0.2	0.3	0.1	-4.0	-1.9	-0.1	0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	11.34	11.44	11.59	11.82	12.01	12.07	8.80	7.24	7.20	7.35
Share Capital ⓘ	8.10	8.10	8.10	8.10	8.10	8.10	8.10	8.10	8.10	8.10
Reserves ⓘ	3.24	3.34	3.49	3.72	3.91	3.97	0.70	-0.86	-0.90	-0.75
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	0.31	0.10	0.01	0.01	0	0.05	0
Others Liabilities ⓘ	0.26	0.20	0.15	0.20	0.02	-0.04	-0.05	-0.06	-0.06	-0.05
Total Liabilities ⓘ	11.60	11.64	11.74	12.33	12.13	12.04	8.77	7.19	7.19	7.31
Fixed Assets
Gross Block	3.27	3.41	3.57	3.74	3.56	3.58	3.58	1.43	1.43	1.41
Accumulated Depreciation	2.52	2.85	2.98	3.13	3.19	3.27	3.35	1.20	1.26	1.30
Net Fixed Assetsⓘ	0.75	0.55	0.59	0.61	0.37	0.31	0.22	0.23	0.17	0.12
CWIP ⓘ	0	0.08	0	0	0	0	0	0	0	0
Investmentsⓘ	1.40	3.01	1.84	2.92	2.72	3.53	3.64	0.59	2.78	3.06
Inventories	0	0	0.22	0.11	0.10	0.08	0.25	0.53	0.82	1.19
Trade Receivables	0.12	0.01	0.40	1.11	2.14	0.08	0.09	0.10	0.19	0.01
Cash Equivalents	0.17	0.44	0.34	0.15	0.16	0.95	1.74	2.60	0.27	0.12
Others Assetsⓘ	9.16	7.54	8.35	7.42	6.63	7.09	2.83	3.13	2.96	2.80
Total Assets ⓘ	11.60	11.64	11.74	12.33	12.13	12.04	8.77	7.19	7.19	7.31

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-0.43	2.03	-1.07	1.08	-0.44	1.21	0.58	0.59	-2.41	-0.34
PBT ⓘ	0.09	0.14	0.20	0.29	0.19	0.11	-3.27	-1.57	-0.06	0.02
Adjustment ⓘ	-0.54	0.26	0.24	0.22	-0.07	-0.36	-0.24	1.04	-0.46	-0.27
Changes in Working Capital ⓘ	0.12	1.73	-1.46	0.66	-0.55	1.51	4.09	1.12	-1.89	-0.1
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-0.25	-1.76	0.97	-1.27	0.45	-0.42	0.21	0.28	0.08	0.19
Capex	-0.10	-0.14	-0.16	-0.21	0.29	-0.01	-0.30	-1.83	0	0.02
Net Investments	-1.29	-1.57	1.03	-1.08	0.16	-0.79	0.19	1.56	2.28	-0.14
Others ⓘ	1.14	-0.05	0.10	0.01	0	0.39	0.31	0.55	-2.20	0.31
Cash Flow From Financing Activityⓘ	-0.01	0	0	0	0	0	0	0	0	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0.01	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Net Cash Flow ⓘ	-0.69	0.27	-0.10	-0.19	0.01	0.79	0.78	0.87	-2.33	-0.16

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0.16	0.86	1.31	1.55	2.1	0.79	-31.32	-19.45	-0.83	0.14
ROCE (%)	0.81	1.2	1.78	2.5	1.6	0.89	-31.33	-19.51	-0.81	0.3
Asset Turnover Ratio	0.12	0.08	0.3	0.26	0.29	0.09	0.1	0.11	0.2	0.58
PAT to CFO Conversion(x)	-21.5	20.3	-7.13	6	-1.76	13.44	N/A	N/A	N/A	-34
Working Capital Days
Receivable Days	121	25	21	88	165	392	30	40	38	9
Inventory Days	0	0	23	19	11	32	59	169	176	87
Payable Days	0	0	0	27	27	27	4	0	15	3

Novelix Pharmaceuticals Ltd Stock News

Novelix Pharmaceuticals Ltd FAQs

What is the share price of Novelix Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Novelix Pharma on 18-Jul-2025 16:59 is ₹46.88.

What is the market cap of Novelix Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Jul-2025 16:59 the market cap of Novelix Pharma stood at ₹60.64.

What is the P/E ratio of Novelix Pharma?

The latest P/E ratio of Novelix Pharma as of 18-Jul-2025 16:59 is 730.6.

What is the P/B ratio of Novelix Pharma?

The latest P/B ratio of Novelix Pharma as of 18-Jul-2025 16:59 is 2.58.

What is the 52-week high and low of Novelix Pharma?

The 52-week high of Novelix Pharma is ₹52.79 and the 52-week low is ₹19.88.

What is the TTM revenue of Novelix Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Novelix Pharma is ₹30.72 ( Cr.) .

About Novelix Pharmaceuticals Ltd

Trimurthi Drugs & Pharmaceuticals is an India-based company. The Company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The Companyâ€™s range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder. The company since 1976 is built on the philosophy of commitment to quality and responsiveness.

2012 -The Company entered into a Manufacturing Agreement with M/s. Bharat Parenterals Limited, Vadodara, Gujrat for exclusive manufacture of Company's 12 products for export. The Company entered into Distribution Agreement with Zyanya Global Pte Limited, Vietnam for selling the Company's Products in Vietnam.

Business areas of the company:

The company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products.

Divisions:

Pharma Business, Financial Services, Investment in Shares and Trading in Shares

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Novelix Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Novelix Pharma Share Price

Novelix Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Novelix Pharma Share Price

DeciZen - make an informed investing decision on Novelix Pharma Share

M-Cap below 100cr DeciZen not available

Novelix Pharmaceuticals stock performance -

Is Novelix Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Novelix Pharmaceuticals Ltd a good quality company?

2. Is Novelix Pharmaceuticals Ltd undervalued or overvalued?

3. Is Novelix Pharmaceuticals Ltd a good buy now?

10 Year X-Ray of Novelix Pharma: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Novelix Pharmaceuticals Ltd.

Management X-Ray of Novelix Pharma: Share

Shareholding Pattern

Promoter's Holding & Share Pledging